View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 16, 2022

Inversago begins dosing with INV-202 in Phase Ib metabolic syndrome trial

The trial will assess the safety profile and pharmacokinetics of INV-202 in patients with metabolic syndrome.

Inversago Pharma has dosed the first subject in a Phase Ib clinical trial of its lead molecule, INV-202, to treat metabolic syndrome.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

INV-202 is a first-in-class, peripheral inhibitor of cannabinoid type 1 receptor. 

The trial will analyse the safety profile and pharmacokinetics of INV-202 in 40 subjects with metabolic syndrome. 

Topline data from the trial is anticipated in the second half of this year.

Inversago CEO Dr François Ravenelle said: “We are pleased that the clinical trials for INV-202, our first-in-class, peripheral CB1 inhibitor, are moving ahead swiftly. 

“This pharmacokinetic and safety study will also measure a number of well accepted biomarkers of metabolic disorders. Together, these results are expected to act as a guide for the next phase of INV-202’s development.”

Peripheral CB1 inverse agonists, such as INV-202, could address various pathways linked to renal injury. 

CB1 inverse agonists were found to offer clinical benefits in lipids, weight reduction and glucose in addition to effects on albuminuria in pre-clinical models. 

Furthermore, these effects each demonstrated to possess reno-protective properties.

The company intends to commence a Phase II trial of diabetic nephropathy (DN) patients on obtaining data from the Phase I trial. 

DN is characterised by chronic loss of kidney function in type-1 and type-2 diabetes patients who also often have obesity. 

This patient profile enables the objective evaluation of DN-specific primary endpoints and secondary endpoints significant to metabolic diseases in general. 

Inversago believes that this indication could offer the necessary proof of concept to show the therapeutic breadth of INV-202 as well as other assets in its pipeline.

In January this year, the company concluded the Phase I trial of INV-202 to treat metabolic disorder complications. 

Findings showed that INV-202 had favourable safety, tolerability and pharmacokinetics to progress to further trials.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena